[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fbHKRcVkt26dyIzPqUNLXkAxlFdxKJw7w6VB0x0x6RaI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":83,"rows":90},"Sichuan University",[4],100,false,51,4,8099,52,19,[14,17,20,23,25,27,29,32],{"name":15,"count":16},"Esophageal Cancer",6,{"name":18,"count":19},"Gastric Cancer",5,{"name":21,"count":22},"Esophageal Squamous Cell Carcinoma (ESCC)",3,{"name":24,"count":22},"Leukemia, Lymphoid",{"name":26,"count":22},"Esophageal Squamous Cell Carcinoma",{"name":28,"count":22},"Extensive-stage Small-cell Lung Cancer",{"name":30,"count":31},"Small Cell Lung Cancer Extensive Stage",2,{"name":33,"count":31},"Pancreatic Cancer",[35,40,45,50,55,60,63,68,73,78],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05682755","Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT","2023-12-31","Chidamide",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT05615142","Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.","2024-04-30","PD-1 Inhibitors",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05765825","Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC","2024-07-31","serplulimab",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT06111625","Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL","2024-08-31","blinatumomab",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06075225","MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib","2024-09-30","Ruxolitinib",{"nctId":61,"briefTitle":62,"date":58,"intervention":54},"NCT06075238","Blinatumomab Prevents Recurrence of R\u002FR ALL After Allo-HSCT",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT06431685","Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer","2025-03-28","Pemetrexed",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT06446726","Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma","2025-06-30","Tislelizumab",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT06033118","Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICC","2025-07-31","gemcitabine ,oxaliplatin,anlotinib,Sintilimab",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT05186506","A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer","2025-12-15","Ensatinib",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,177,274,334,387,432,472,500,529,561,630,662,688,706,727,745,769,787,810,833,851,877,895,920,938,956,974,992,1018,1043,1068,1086,1104,1122,1140,1158,1199,1222,1246,1267,1293,1317,1335,1353,1371,1394,1417,1435,1458,1480,1503,1529,1552,1582,1608,1626,1644,1670,1696,1724,1742,1760,1778,1796,1814,1832,1860,1884,1911,1937,1955,1973,1996,2020,2045,2063,2081,2099,2117,2135,2160,2184,2208,2231,2255,2279,2302,2327,2353,2371,2396,2422,2448,2466,2490,2513,2539,2557],{"intervention":92,"totalTrials":16,"cells":93},"Chemotherapy",{"EARLY_PHASE1":94,"PHASE1":97,"PHASE2":113,"PHASE3":171,"PHASE4":173,"NA":175},{"trials":95,"activeCount":96},[],0,{"trials":98,"activeCount":112,"soonestReadout":66},[99],{"nctId":64,"briefTitle":65,"status":100,"phases":101,"primaryCompletion":66,"completion":102,"start":103,"enrollment":104,"conditions":105,"interventions":110},"RECRUITING",[85],"2026-12-31","2024-04-25",10,[106,107,108,109],"NSCLC","Low Dose Radiotherapy","PD-1 Inhibitor","Leptomeningeal Metastasis",[67,111,92],"Sintilimab",1,{"trials":114,"activeCount":19,"soonestReadout":81},[115,128,139,150,160],{"nctId":116,"briefTitle":117,"status":118,"phases":119,"primaryCompletion":120,"completion":121,"start":122,"enrollment":123,"conditions":124,"interventions":126},"NCT07258147","Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases","NOT_YET_RECRUITING",[86],"2027-12-31","2028-12-30","2026-10-31",30,[125],"Lung Cancer (SCLC)",[127,92],"Immunotherapy",{"nctId":79,"briefTitle":80,"status":118,"phases":129,"primaryCompletion":81,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":137},[86],"2028-12-20","2022-01-01",152,[134,135,136],"ALK Fusion Protein Expression","Adjuvant Therapy","Non-Small Cell Lung Cancer",[82,138],"chemotherapy",{"nctId":140,"briefTitle":141,"status":100,"phases":142,"primaryCompletion":143,"completion":121,"start":144,"enrollment":145,"conditions":146,"interventions":148},"NCT06195189","Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I\u002FII",[85,86],"2027-12-30","2024-02-29",40,[147],"Non Small Cell Lung Cancer",[149,92],"Sunvozertinib",{"nctId":151,"briefTitle":152,"status":100,"phases":153,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":157,"interventions":159},"NCT06121505","Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer",[86],"2027-02-28","2024-03-01",114,[158],"Lung Squamous Cell Carcinoma",[138,111],{"nctId":161,"briefTitle":162,"status":100,"phases":163,"primaryCompletion":164,"completion":165,"start":166,"enrollment":167,"conditions":168,"interventions":169},"NCT06610734","Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)",[86],"2026-12","2028-12","2024-12-23",202,[30],[170,92],"Adebrelimab",{"trials":172,"activeCount":96},[],{"trials":174,"activeCount":96},[],{"trials":176,"activeCount":96},[],{"intervention":178,"totalTrials":179,"cells":180},"Carboplatin",7,{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":199,"PHASE3":254,"PHASE4":256,"NA":272},{"trials":182,"activeCount":96},[],{"trials":184,"activeCount":96},[185],{"nctId":186,"briefTitle":187,"status":188,"phases":189,"primaryCompletion":190,"completion":191,"start":192,"enrollment":96,"conditions":193,"interventions":194},"NCT06732258","Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC","WITHDRAWN",[85],"2026-02-28","2028-02-29","2025-01-10",[28],[195,196,197,178,198],"Tifcemalimab","Toripalimab","Cisplatin","Etoposide",{"trials":200,"activeCount":9,"soonestReadout":48},[201,208,219,233,244],{"nctId":46,"briefTitle":47,"status":202,"phases":203,"primaryCompletion":48,"completion":102,"start":204,"enrollment":205,"conditions":206,"interventions":207},"ACTIVE_NOT_RECRUITING",[86],"2023-03-07",61,[28],[49,197,178,198],{"nctId":209,"briefTitle":210,"status":100,"phases":211,"primaryCompletion":212,"completion":213,"start":214,"enrollment":215,"conditions":216,"interventions":217},"NCT06403878","Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer",[86],"2026-05","2026-08","2024-05",68,[15],[178,218,111],"Nab paclitaxel",{"nctId":220,"briefTitle":221,"status":222,"phases":223,"primaryCompletion":224,"completion":225,"start":226,"enrollment":227,"conditions":228,"interventions":230},"NCT05900921","Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer","UNKNOWN",[86],"2024-10-31","2025-12-31","2023-07-01",132,[229],"Advanced Squamous Non-Small-Cell Lung Cancer",[231,178,232,72],"Trilaciclib","Paclitaxel",{"nctId":234,"briefTitle":235,"status":100,"phases":236,"primaryCompletion":102,"completion":120,"start":237,"enrollment":238,"conditions":239,"interventions":241},"NCT06769971","Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC",[86],"2025-02-01",80,[240],"Small Cell Lung Cancer",[242,243,198,178],"Ivonescimab","Cadonilimab",{"nctId":245,"briefTitle":246,"status":202,"phases":247,"primaryCompletion":102,"completion":120,"start":248,"enrollment":249,"conditions":250,"interventions":252},"NCT06477523","Phase 1b\u002F2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC",[85,86],"2024-05-16",57,[251],"SCLC, Extensive Stage",[253,198,178],"AK104",{"trials":255,"activeCount":96},[],{"trials":257,"activeCount":96},[258],{"nctId":259,"briefTitle":260,"status":261,"phases":262,"primaryCompletion":263,"completion":263,"start":264,"enrollment":205,"conditions":265,"interventions":268},"NCT02299765","Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC","TERMINATED",[88],"2017-10","2014-12",[266,267],"Non-small Cell Lung Cancer Metastatic","EGFR Activating Mutation",[269,270,271],"Gefitinib","gemcitabine","carboplatin",{"trials":273,"activeCount":96},[],{"intervention":198,"totalTrials":16,"cells":275},{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":284,"PHASE3":311,"PHASE4":330,"NA":332},{"trials":277,"activeCount":96},[],{"trials":279,"activeCount":96},[280],{"nctId":186,"briefTitle":187,"status":188,"phases":281,"primaryCompletion":190,"completion":191,"start":192,"enrollment":96,"conditions":282,"interventions":283},[85],[28],[195,196,197,178,198],{"trials":285,"activeCount":9,"soonestReadout":48},[286,290,294,298],{"nctId":46,"briefTitle":47,"status":202,"phases":287,"primaryCompletion":48,"completion":102,"start":204,"enrollment":205,"conditions":288,"interventions":289},[86],[28],[49,197,178,198],{"nctId":234,"briefTitle":235,"status":100,"phases":291,"primaryCompletion":102,"completion":120,"start":237,"enrollment":238,"conditions":292,"interventions":293},[86],[240],[242,243,198,178],{"nctId":245,"briefTitle":246,"status":202,"phases":295,"primaryCompletion":102,"completion":120,"start":248,"enrollment":249,"conditions":296,"interventions":297},[85,86],[251],[253,198,178],{"nctId":299,"briefTitle":300,"status":100,"phases":301,"primaryCompletion":302,"completion":303,"start":304,"enrollment":305,"conditions":306,"interventions":308},"NCT06217757","Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC",[85,86],"2027-10-31","2028-10-31","2024-04-18",45,[307,28],"Lung Cancer",[198,197,309,310],"Sugemalimab","Olaparib",{"trials":312,"activeCount":96},[313],{"nctId":314,"briefTitle":315,"status":222,"phases":316,"primaryCompletion":317,"completion":317,"start":318,"enrollment":319,"conditions":320,"interventions":323},"NCT05466318","ChiCGB vs BEAM in High-risk or R\u002FR Lymphomas",[87],"2025-12-30","2022-07-01",306,[321,322],"Lymphoma, Large B-Cell, Diffuse","Lymphoma, T-Cell",[39,324,325,326,327,198,328,329],"Cladribine","Gemcitabine","Busulfan","Carmustine","Cytarabine","Melphalan",{"trials":331,"activeCount":96},[],{"trials":333,"activeCount":96},[],{"intervention":111,"totalTrials":19,"cells":335},{"EARLY_PHASE1":336,"PHASE1":338,"PHASE2":356,"PHASE3":381,"PHASE4":383,"NA":385},{"trials":337,"activeCount":96},[],{"trials":339,"activeCount":112,"soonestReadout":66},[340,352],{"nctId":341,"briefTitle":342,"status":343,"phases":344,"primaryCompletion":345,"completion":346,"start":347,"enrollment":348,"conditions":349,"interventions":351},"NCT03812549","Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients","COMPLETED",[85],"2022-01-31","2022-07-08","2019-01-18",29,[350],"Stage IV NSCLC",[111],{"nctId":64,"briefTitle":65,"status":100,"phases":353,"primaryCompletion":66,"completion":102,"start":103,"enrollment":104,"conditions":354,"interventions":355},[85],[106,107,108,109],[67,111,92],{"trials":357,"activeCount":31,"soonestReadout":212},[358,373,377],{"nctId":359,"briefTitle":360,"status":222,"phases":361,"primaryCompletion":362,"completion":363,"start":364,"enrollment":365,"conditions":366,"interventions":371},"NCT04263870","Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction",[86],"2021-05","2021-10","2020-03",36,[367,368,369,370],"Gastroesophageal Junction Adenocarcinoma","Stomach Adenocarcinoma","Locally Advanced Unresectable Gastric Adenocarcinoma","Metastatic Gastric Cancer",[372],"sintilimab",{"nctId":209,"briefTitle":210,"status":100,"phases":374,"primaryCompletion":212,"completion":213,"start":214,"enrollment":215,"conditions":375,"interventions":376},[86],[15],[178,218,111],{"nctId":151,"briefTitle":152,"status":100,"phases":378,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":379,"interventions":380},[86],[158],[138,111],{"trials":382,"activeCount":96},[],{"trials":384,"activeCount":96},[],{"trials":386,"activeCount":96},[],{"intervention":72,"totalTrials":9,"cells":388},{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":403,"PHASE3":426,"PHASE4":428,"NA":430},{"trials":390,"activeCount":96},[],{"trials":392,"activeCount":112,"soonestReadout":397},[393],{"nctId":394,"briefTitle":395,"status":100,"phases":396,"primaryCompletion":397,"completion":398,"start":304,"enrollment":399,"conditions":400,"interventions":402},"NCT06349837","Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors",[85],"2028-03-31","2028-11-30",24,[401],"Solid Tumor",[72],{"trials":404,"activeCount":31,"soonestReadout":71},[405,412,416],{"nctId":69,"briefTitle":70,"status":100,"phases":406,"primaryCompletion":71,"completion":407,"start":408,"enrollment":123,"conditions":409,"interventions":410},[86],"2026-12-30","2024-06-30",[26],[72,411,197],"Nab-paclitaxel",{"nctId":220,"briefTitle":221,"status":222,"phases":413,"primaryCompletion":224,"completion":225,"start":226,"enrollment":227,"conditions":414,"interventions":415},[86],[229],[231,178,232,72],{"nctId":417,"briefTitle":418,"status":118,"phases":419,"primaryCompletion":420,"completion":420,"start":421,"enrollment":422,"conditions":423,"interventions":425},"NCT06883552","An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer",[86],"2026-10-01","2025-10-01",21,[424],"Lung Cancer (NSCLC)",[72],{"trials":427,"activeCount":96},[],{"trials":429,"activeCount":96},[],{"trials":431,"activeCount":96},[],{"intervention":197,"totalTrials":19,"cells":433},{"EARLY_PHASE1":434,"PHASE1":436,"PHASE2":442,"PHASE3":456,"PHASE4":458,"NA":460},{"trials":435,"activeCount":96},[],{"trials":437,"activeCount":96},[438],{"nctId":186,"briefTitle":187,"status":188,"phases":439,"primaryCompletion":190,"completion":191,"start":192,"enrollment":96,"conditions":440,"interventions":441},[85],[28],[195,196,197,178,198],{"trials":443,"activeCount":22,"soonestReadout":48},[444,448,452],{"nctId":69,"briefTitle":70,"status":100,"phases":445,"primaryCompletion":71,"completion":407,"start":408,"enrollment":123,"conditions":446,"interventions":447},[86],[26],[72,411,197],{"nctId":46,"briefTitle":47,"status":202,"phases":449,"primaryCompletion":48,"completion":102,"start":204,"enrollment":205,"conditions":450,"interventions":451},[86],[28],[49,197,178,198],{"nctId":299,"briefTitle":300,"status":100,"phases":453,"primaryCompletion":302,"completion":303,"start":304,"enrollment":305,"conditions":454,"interventions":455},[85,86],[307,28],[198,197,309,310],{"trials":457,"activeCount":96},[],{"trials":459,"activeCount":96},[],{"trials":461,"activeCount":96},[462],{"nctId":463,"briefTitle":464,"status":222,"phases":465,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":469,"interventions":471},"NCT03559803","A Prospective Study of Monitoring Immune Response in Locally Advanced Cervix Cancer",[89],"2019-12","2016-10",58,[470],"Cervical Cancer",[197],{"intervention":127,"totalTrials":31,"cells":473},{"EARLY_PHASE1":474,"PHASE1":476,"PHASE2":488,"PHASE3":494,"PHASE4":496,"NA":498},{"trials":475,"activeCount":96},[],{"trials":477,"activeCount":112,"soonestReadout":482},[478],{"nctId":479,"briefTitle":480,"status":118,"phases":481,"primaryCompletion":482,"completion":483,"start":484,"enrollment":485,"conditions":486,"interventions":487},"NCT06966583","NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC",[85],"2027-06-30","2027-11-30","2025-05-01",20,[401,147],[127],{"trials":489,"activeCount":112,"soonestReadout":120},[490],{"nctId":116,"briefTitle":117,"status":118,"phases":491,"primaryCompletion":120,"completion":121,"start":122,"enrollment":123,"conditions":492,"interventions":493},[86],[125],[127,92],{"trials":495,"activeCount":96},[],{"trials":497,"activeCount":96},[],{"trials":499,"activeCount":96},[],{"intervention":242,"totalTrials":31,"cells":501},{"EARLY_PHASE1":502,"PHASE1":504,"PHASE2":506,"PHASE3":523,"PHASE4":525,"NA":527},{"trials":503,"activeCount":96},[],{"trials":505,"activeCount":96},[],{"trials":507,"activeCount":31,"soonestReadout":102},[508,519],{"nctId":509,"briefTitle":510,"status":118,"phases":511,"primaryCompletion":120,"completion":120,"start":512,"enrollment":513,"conditions":514,"interventions":516},"NCT07374250","Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma",[86],"2026-02-01",154,[18,515],"RCT",[242,517,518],"Oxaliplatin","S-1",{"nctId":234,"briefTitle":235,"status":100,"phases":520,"primaryCompletion":102,"completion":120,"start":237,"enrollment":238,"conditions":521,"interventions":522},[86],[240],[242,243,198,178],{"trials":524,"activeCount":96},[],{"trials":526,"activeCount":96},[],{"trials":528,"activeCount":96},[],{"intervention":54,"totalTrials":22,"cells":530},{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":535,"PHASE3":549,"PHASE4":551,"NA":553},{"trials":532,"activeCount":96},[],{"trials":534,"activeCount":96},[],{"trials":536,"activeCount":31,"soonestReadout":53},[537,543],{"nctId":51,"briefTitle":52,"status":100,"phases":538,"primaryCompletion":53,"completion":539,"start":540,"enrollment":485,"conditions":541,"interventions":542},[86],"2026-08-31","2023-09-10",[24],[54],{"nctId":61,"briefTitle":62,"status":118,"phases":544,"primaryCompletion":58,"completion":545,"start":546,"enrollment":215,"conditions":547,"interventions":548},[86],"2026-09-30","2023-10-01",[24],[54],{"trials":550,"activeCount":96},[],{"trials":552,"activeCount":96},[],{"trials":554,"activeCount":96},[555],{"nctId":556,"briefTitle":557,"status":222,"phases":558,"primaryCompletion":58,"completion":58,"start":546,"enrollment":485,"conditions":559,"interventions":560},"NCT06075212","Immune Reconstitution After Allo-HSCT and Blinatumomab",[],[24],[54],{"intervention":39,"totalTrials":16,"cells":562},{"EARLY_PHASE1":563,"PHASE1":565,"PHASE2":567,"PHASE3":620,"PHASE4":626,"NA":628},{"trials":564,"activeCount":96},[],{"trials":566,"activeCount":96},[],{"trials":568,"activeCount":112,"soonestReadout":38},[569,583,594,601,609],{"nctId":570,"briefTitle":571,"status":222,"phases":572,"primaryCompletion":573,"completion":574,"start":575,"enrollment":576,"conditions":577,"interventions":580},"NCT03336632","Chidamide Plus PTCy\u002FCyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT",[86],"2020-12-30","2021-03-30","2019-01-01",50,[578,579],"Leukemia, Acute","MDS",[39,581,582],"Cyclophosphamide","cyclosporine A",{"nctId":584,"briefTitle":585,"status":222,"phases":586,"primaryCompletion":587,"completion":588,"start":575,"enrollment":485,"conditions":589,"interventions":591},"NCT03598959","Tofacitinib Combined With Chidamide in R\u002FR ENKTCL",[86],"2019-12-31","2021-12-31",[590],"Extranodal NK\u002FT-cell Lymphoma",[592,593],"tofacitinib","chidamide",{"nctId":36,"briefTitle":37,"status":100,"phases":595,"primaryCompletion":38,"completion":102,"start":596,"enrollment":597,"conditions":598,"interventions":600},[85,86],"2022-12-22",77,[599],"Leukemia, Myeloid, Acute",[39],{"nctId":602,"briefTitle":603,"status":222,"phases":604,"primaryCompletion":573,"completion":574,"start":575,"enrollment":123,"conditions":605,"interventions":608},"NCT03602131","Chidamide Combined With Clad\u002FGem\u002FBu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma",[86],[606,607],"Hodgkin Lymphoma","Non-hodgkin Lymphoma",[39,324,270,326],{"nctId":610,"briefTitle":611,"status":222,"phases":612,"primaryCompletion":613,"completion":614,"start":615,"enrollment":616,"conditions":617,"interventions":619},"NCT03151876","Chidamide Combined With Clad\u002FGem\u002FBu With AutoSCT in R\u002FR Diffuse Large B Cell Lymphoma",[86],"2020-12","2021-12","2017-06-12",93,[618],"Lymphoma",[39,324,270,326],{"trials":621,"activeCount":96},[622],{"nctId":314,"briefTitle":315,"status":222,"phases":623,"primaryCompletion":317,"completion":317,"start":318,"enrollment":319,"conditions":624,"interventions":625},[87],[321,322],[39,324,325,326,327,198,328,329],{"trials":627,"activeCount":96},[],{"trials":629,"activeCount":96},[],{"intervention":59,"totalTrials":31,"cells":631},{"EARLY_PHASE1":632,"PHASE1":634,"PHASE2":636,"PHASE3":656,"PHASE4":658,"NA":660},{"trials":633,"activeCount":96},[],{"trials":635,"activeCount":96},[],{"trials":637,"activeCount":112,"soonestReadout":58},[638,645],{"nctId":56,"briefTitle":57,"status":118,"phases":639,"primaryCompletion":58,"completion":545,"start":546,"enrollment":640,"conditions":641,"interventions":644},[86],62,[642,643],"GVHD","Acute Stem Cell Transplant Complications",[59],{"nctId":646,"briefTitle":647,"status":222,"phases":648,"primaryCompletion":573,"completion":574,"start":649,"enrollment":650,"conditions":651,"interventions":653},"NCT03613428","Ruxolitinib Plus LVP in Patients With R\u002FR ETP-ALL",[85,86],"2018-12-01",12,[652],"Acute T Cell Leukemia",[59,654,655],"Vincristine","Prednisone",{"trials":657,"activeCount":96},[],{"trials":659,"activeCount":96},[],{"trials":661,"activeCount":96},[],{"intervention":663,"totalTrials":112,"cells":664},"neoantigen-loaded dendritic cell vaccine",{"EARLY_PHASE1":665,"PHASE1":667,"PHASE2":669,"PHASE3":682,"PHASE4":684,"NA":686},{"trials":666,"activeCount":96},[],{"trials":668,"activeCount":96},[],{"trials":670,"activeCount":112,"soonestReadout":675},[671],{"nctId":672,"briefTitle":673,"status":100,"phases":674,"primaryCompletion":675,"completion":675,"start":676,"enrollment":677,"conditions":678,"interventions":681},"NCT06675201","Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma",[86],"2027-10-01","2024-10-01",165,[21,679,680],"Neoantigen-loaded Dendritic Cell Vaccine","Immune Checkpoint Inhibitors (ICIs)",[663],{"trials":683,"activeCount":96},[],{"trials":685,"activeCount":96},[],{"trials":687,"activeCount":96},[],{"intervention":411,"totalTrials":112,"cells":689},{"EARLY_PHASE1":690,"PHASE1":692,"PHASE2":694,"PHASE3":700,"PHASE4":702,"NA":704},{"trials":691,"activeCount":96},[],{"trials":693,"activeCount":96},[],{"trials":695,"activeCount":112,"soonestReadout":71},[696],{"nctId":69,"briefTitle":70,"status":100,"phases":697,"primaryCompletion":71,"completion":407,"start":408,"enrollment":123,"conditions":698,"interventions":699},[86],[26],[72,411,197],{"trials":701,"activeCount":96},[],{"trials":703,"activeCount":96},[],{"trials":705,"activeCount":96},[],{"intervention":77,"totalTrials":112,"cells":707},{"EARLY_PHASE1":708,"PHASE1":710,"PHASE2":712,"PHASE3":721,"PHASE4":723,"NA":725},{"trials":709,"activeCount":96},[],{"trials":711,"activeCount":96},[],{"trials":713,"activeCount":112,"soonestReadout":76},[714],{"nctId":74,"briefTitle":75,"status":118,"phases":715,"primaryCompletion":76,"completion":716,"start":546,"enrollment":717,"conditions":718,"interventions":720},[85,86],"2026-08-01",25,[719],"Combined Hepatocellular Cholangiocarcinoma",[77],{"trials":722,"activeCount":96},[],{"trials":724,"activeCount":96},[],{"trials":726,"activeCount":96},[],{"intervention":82,"totalTrials":112,"cells":728},{"EARLY_PHASE1":729,"PHASE1":731,"PHASE2":733,"PHASE3":739,"PHASE4":741,"NA":743},{"trials":730,"activeCount":96},[],{"trials":732,"activeCount":96},[],{"trials":734,"activeCount":112,"soonestReadout":81},[735],{"nctId":79,"briefTitle":80,"status":118,"phases":736,"primaryCompletion":81,"completion":130,"start":131,"enrollment":132,"conditions":737,"interventions":738},[86],[134,135,136],[82,138],{"trials":740,"activeCount":96},[],{"trials":742,"activeCount":96},[],{"trials":744,"activeCount":96},[],{"intervention":746,"totalTrials":112,"cells":747},"Low-Dose Radiation",{"EARLY_PHASE1":748,"PHASE1":750,"PHASE2":752,"PHASE3":763,"PHASE4":765,"NA":767},{"trials":749,"activeCount":96},[],{"trials":751,"activeCount":96},[],{"trials":753,"activeCount":112,"soonestReadout":482},[754],{"nctId":755,"briefTitle":756,"status":100,"phases":757,"primaryCompletion":482,"completion":758,"start":759,"enrollment":123,"conditions":760,"interventions":762},"NCT06877299","Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer",[86],"2028-01-01","2025-07-04",[307,761],"Non-small Cell Lung Cancer",[746],{"trials":764,"activeCount":96},[],{"trials":766,"activeCount":96},[],{"trials":768,"activeCount":96},[],{"intervention":49,"totalTrials":112,"cells":770},{"EARLY_PHASE1":771,"PHASE1":773,"PHASE2":775,"PHASE3":781,"PHASE4":783,"NA":785},{"trials":772,"activeCount":96},[],{"trials":774,"activeCount":96},[],{"trials":776,"activeCount":112,"soonestReadout":48},[777],{"nctId":46,"briefTitle":47,"status":202,"phases":778,"primaryCompletion":48,"completion":102,"start":204,"enrollment":205,"conditions":779,"interventions":780},[86],[28],[49,197,178,198],{"trials":782,"activeCount":96},[],{"trials":784,"activeCount":96},[],{"trials":786,"activeCount":96},[],{"intervention":788,"totalTrials":112,"cells":789},"AK112",{"EARLY_PHASE1":790,"PHASE1":792,"PHASE2":794,"PHASE3":804,"PHASE4":806,"NA":808},{"trials":791,"activeCount":96},[],{"trials":793,"activeCount":96},[],{"trials":795,"activeCount":112,"soonestReadout":102},[796],{"nctId":797,"briefTitle":798,"status":100,"phases":799,"primaryCompletion":102,"completion":120,"start":237,"enrollment":800,"conditions":801,"interventions":803},"NCT06769295","A Phase II Study of AK112 (PD1\u002FVEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC",[86],28,[802],"Lung Cancer, Non-Small Cell",[788],{"trials":805,"activeCount":96},[],{"trials":807,"activeCount":96},[],{"trials":809,"activeCount":96},[],{"intervention":811,"totalTrials":112,"cells":812},"High dose Gemcitabine, Busulfan, and Thiotepa as conditioning therapy",{"EARLY_PHASE1":813,"PHASE1":815,"PHASE2":817,"PHASE3":827,"PHASE4":829,"NA":831},{"trials":814,"activeCount":96},[],{"trials":816,"activeCount":96},[],{"trials":818,"activeCount":112,"soonestReadout":102},[819],{"nctId":820,"briefTitle":821,"status":100,"phases":822,"primaryCompletion":102,"completion":102,"start":131,"enrollment":823,"conditions":824,"interventions":826},"NCT07014943","High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma",[86],34,[825],"Primary Central Nervous System Lymphoma (PCNSL)",[811],{"trials":828,"activeCount":96},[],{"trials":830,"activeCount":96},[],{"trials":832,"activeCount":96},[],{"intervention":218,"totalTrials":112,"cells":834},{"EARLY_PHASE1":835,"PHASE1":837,"PHASE2":839,"PHASE3":845,"PHASE4":847,"NA":849},{"trials":836,"activeCount":96},[],{"trials":838,"activeCount":96},[],{"trials":840,"activeCount":112,"soonestReadout":212},[841],{"nctId":209,"briefTitle":210,"status":100,"phases":842,"primaryCompletion":212,"completion":213,"start":214,"enrollment":215,"conditions":843,"interventions":844},[86],[15],[178,218,111],{"trials":846,"activeCount":96},[],{"trials":848,"activeCount":96},[],{"trials":850,"activeCount":96},[],{"intervention":852,"totalTrials":112,"cells":853},"PD-1 Inhibitor plus Chemotherapy",{"EARLY_PHASE1":854,"PHASE1":856,"PHASE2":858,"PHASE3":871,"PHASE4":873,"NA":875},{"trials":855,"activeCount":96},[],{"trials":857,"activeCount":96},[],{"trials":859,"activeCount":112,"soonestReadout":864},[860],{"nctId":861,"briefTitle":862,"status":100,"phases":863,"primaryCompletion":864,"completion":865,"start":866,"enrollment":867,"conditions":868,"interventions":870},"NCT07519486","Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC",[86],"2027-09","2028-03","2026-04",118,[26,869],"Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma",[852],{"trials":872,"activeCount":96},[],{"trials":874,"activeCount":96},[],{"trials":876,"activeCount":96},[],{"intervention":149,"totalTrials":112,"cells":878},{"EARLY_PHASE1":879,"PHASE1":881,"PHASE2":883,"PHASE3":889,"PHASE4":891,"NA":893},{"trials":880,"activeCount":96},[],{"trials":882,"activeCount":96},[],{"trials":884,"activeCount":112,"soonestReadout":143},[885],{"nctId":140,"briefTitle":141,"status":100,"phases":886,"primaryCompletion":143,"completion":121,"start":144,"enrollment":145,"conditions":887,"interventions":888},[85,86],[147],[149,92],{"trials":890,"activeCount":96},[],{"trials":892,"activeCount":96},[],{"trials":894,"activeCount":96},[],{"intervention":896,"totalTrials":112,"cells":897},"Oncolytic Virus: Administered via intratumoral injection (metastatic lesions in the neck or supraclavicular lymph nodes) once every 3 weeks, for a total of two to four doses.",{"EARLY_PHASE1":898,"PHASE1":900,"PHASE2":902,"PHASE3":914,"PHASE4":916,"NA":918},{"trials":899,"activeCount":96},[],{"trials":901,"activeCount":96},[],{"trials":903,"activeCount":112,"soonestReadout":908},[904],{"nctId":905,"briefTitle":906,"status":100,"phases":907,"primaryCompletion":908,"completion":909,"start":910,"enrollment":145,"conditions":911,"interventions":912},"NCT07061704","Oncolytic Virus in Esophageal Squamous Cell Carcinoma",[85,86],"2027-08-01","2027-09-01","2025-08-01",[15],[896,913],"Oncolytic Virus: Administered via intratumoral injection (primary lesions) once every 3 weeks, for a total of two to four doses.",{"trials":915,"activeCount":96},[],{"trials":917,"activeCount":96},[],{"trials":919,"activeCount":96},[],{"intervention":913,"totalTrials":112,"cells":921},{"EARLY_PHASE1":922,"PHASE1":924,"PHASE2":926,"PHASE3":932,"PHASE4":934,"NA":936},{"trials":923,"activeCount":96},[],{"trials":925,"activeCount":96},[],{"trials":927,"activeCount":112,"soonestReadout":908},[928],{"nctId":905,"briefTitle":906,"status":100,"phases":929,"primaryCompletion":908,"completion":909,"start":910,"enrollment":145,"conditions":930,"interventions":931},[85,86],[15],[896,913],{"trials":933,"activeCount":96},[],{"trials":935,"activeCount":96},[],{"trials":937,"activeCount":96},[],{"intervention":517,"totalTrials":112,"cells":939},{"EARLY_PHASE1":940,"PHASE1":942,"PHASE2":944,"PHASE3":950,"PHASE4":952,"NA":954},{"trials":941,"activeCount":96},[],{"trials":943,"activeCount":96},[],{"trials":945,"activeCount":112,"soonestReadout":120},[946],{"nctId":509,"briefTitle":510,"status":118,"phases":947,"primaryCompletion":120,"completion":120,"start":512,"enrollment":513,"conditions":948,"interventions":949},[86],[18,515],[242,517,518],{"trials":951,"activeCount":96},[],{"trials":953,"activeCount":96},[],{"trials":955,"activeCount":96},[],{"intervention":518,"totalTrials":112,"cells":957},{"EARLY_PHASE1":958,"PHASE1":960,"PHASE2":962,"PHASE3":968,"PHASE4":970,"NA":972},{"trials":959,"activeCount":96},[],{"trials":961,"activeCount":96},[],{"trials":963,"activeCount":112,"soonestReadout":120},[964],{"nctId":509,"briefTitle":510,"status":118,"phases":965,"primaryCompletion":120,"completion":120,"start":512,"enrollment":513,"conditions":966,"interventions":967},[86],[18,515],[242,517,518],{"trials":969,"activeCount":96},[],{"trials":971,"activeCount":96},[],{"trials":973,"activeCount":96},[],{"intervention":243,"totalTrials":112,"cells":975},{"EARLY_PHASE1":976,"PHASE1":978,"PHASE2":980,"PHASE3":986,"PHASE4":988,"NA":990},{"trials":977,"activeCount":96},[],{"trials":979,"activeCount":96},[],{"trials":981,"activeCount":112,"soonestReadout":102},[982],{"nctId":234,"briefTitle":235,"status":100,"phases":983,"primaryCompletion":102,"completion":120,"start":237,"enrollment":238,"conditions":984,"interventions":985},[86],[240],[242,243,198,178],{"trials":987,"activeCount":96},[],{"trials":989,"activeCount":96},[],{"trials":991,"activeCount":96},[],{"intervention":993,"totalTrials":112,"cells":994},"Sacituzumab Tirumotecan and Anlotinib",{"EARLY_PHASE1":995,"PHASE1":997,"PHASE2":999,"PHASE3":1012,"PHASE4":1014,"NA":1016},{"trials":996,"activeCount":96},[],{"trials":998,"activeCount":96},[],{"trials":1000,"activeCount":112,"soonestReadout":1005},[1001],{"nctId":1002,"briefTitle":1003,"status":118,"phases":1004,"primaryCompletion":1005,"completion":1006,"start":1007,"enrollment":1008,"conditions":1009,"interventions":1011},"NCT07501169","Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)",[86],"2027-08-31","2028-12-31","2026-04-01",33,[1010],"Extensive-stage Small Cell Lung Cancer (ES-SCLC)",[993],{"trials":1013,"activeCount":96},[],{"trials":1015,"activeCount":96},[],{"trials":1017,"activeCount":96},[],{"intervention":1019,"totalTrials":112,"cells":1020},"S-1, Oxaliplatin sintilimab HIPEC",{"EARLY_PHASE1":1021,"PHASE1":1023,"PHASE2":1025,"PHASE3":1037,"PHASE4":1039,"NA":1041},{"trials":1022,"activeCount":96},[],{"trials":1024,"activeCount":96},[],{"trials":1026,"activeCount":112,"soonestReadout":1031},[1027],{"nctId":1028,"briefTitle":1029,"status":118,"phases":1030,"primaryCompletion":1031,"completion":482,"start":1032,"enrollment":1033,"conditions":1034,"interventions":1036},"NCT06213519","HIPEC Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis",[86],"2027-05-30","2024-02-20",69,[1035,18],"Peritoneal Metastases",[1019],{"trials":1038,"activeCount":96},[],{"trials":1040,"activeCount":96},[],{"trials":1042,"activeCount":96},[],{"intervention":1044,"totalTrials":112,"cells":1045},"BL-B01D1",{"EARLY_PHASE1":1046,"PHASE1":1048,"PHASE2":1050,"PHASE3":1062,"PHASE4":1064,"NA":1066},{"trials":1047,"activeCount":96},[],{"trials":1049,"activeCount":96},[],{"trials":1051,"activeCount":112,"soonestReadout":1056},[1052],{"nctId":1053,"briefTitle":1054,"status":100,"phases":1055,"primaryCompletion":1056,"completion":1057,"start":1058,"enrollment":145,"conditions":1059,"interventions":1060},"NCT06951464","A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC",[86],"2027-05-05","2029-03-05","2025-06-25",[136],[1044,1061],"Almonertinib",{"trials":1063,"activeCount":96},[],{"trials":1065,"activeCount":96},[],{"trials":1067,"activeCount":96},[],{"intervention":1061,"totalTrials":112,"cells":1069},{"EARLY_PHASE1":1070,"PHASE1":1072,"PHASE2":1074,"PHASE3":1080,"PHASE4":1082,"NA":1084},{"trials":1071,"activeCount":96},[],{"trials":1073,"activeCount":96},[],{"trials":1075,"activeCount":112,"soonestReadout":1056},[1076],{"nctId":1053,"briefTitle":1054,"status":100,"phases":1077,"primaryCompletion":1056,"completion":1057,"start":1058,"enrollment":145,"conditions":1078,"interventions":1079},[86],[136],[1044,1061],{"trials":1081,"activeCount":96},[],{"trials":1083,"activeCount":96},[],{"trials":1085,"activeCount":96},[],{"intervention":253,"totalTrials":112,"cells":1087},{"EARLY_PHASE1":1088,"PHASE1":1090,"PHASE2":1092,"PHASE3":1098,"PHASE4":1100,"NA":1102},{"trials":1089,"activeCount":96},[],{"trials":1091,"activeCount":96},[],{"trials":1093,"activeCount":112,"soonestReadout":102},[1094],{"nctId":245,"briefTitle":246,"status":202,"phases":1095,"primaryCompletion":102,"completion":120,"start":248,"enrollment":249,"conditions":1096,"interventions":1097},[85,86],[251],[253,198,178],{"trials":1099,"activeCount":96},[],{"trials":1101,"activeCount":96},[],{"trials":1103,"activeCount":96},[],{"intervention":309,"totalTrials":112,"cells":1105},{"EARLY_PHASE1":1106,"PHASE1":1108,"PHASE2":1110,"PHASE3":1116,"PHASE4":1118,"NA":1120},{"trials":1107,"activeCount":96},[],{"trials":1109,"activeCount":96},[],{"trials":1111,"activeCount":112,"soonestReadout":302},[1112],{"nctId":299,"briefTitle":300,"status":100,"phases":1113,"primaryCompletion":302,"completion":303,"start":304,"enrollment":305,"conditions":1114,"interventions":1115},[85,86],[307,28],[198,197,309,310],{"trials":1117,"activeCount":96},[],{"trials":1119,"activeCount":96},[],{"trials":1121,"activeCount":96},[],{"intervention":310,"totalTrials":112,"cells":1123},{"EARLY_PHASE1":1124,"PHASE1":1126,"PHASE2":1128,"PHASE3":1134,"PHASE4":1136,"NA":1138},{"trials":1125,"activeCount":96},[],{"trials":1127,"activeCount":96},[],{"trials":1129,"activeCount":112,"soonestReadout":302},[1130],{"nctId":299,"briefTitle":300,"status":100,"phases":1131,"primaryCompletion":302,"completion":303,"start":304,"enrollment":305,"conditions":1132,"interventions":1133},[85,86],[307,28],[198,197,309,310],{"trials":1135,"activeCount":96},[],{"trials":1137,"activeCount":96},[],{"trials":1139,"activeCount":96},[],{"intervention":170,"totalTrials":112,"cells":1141},{"EARLY_PHASE1":1142,"PHASE1":1144,"PHASE2":1146,"PHASE3":1152,"PHASE4":1154,"NA":1156},{"trials":1143,"activeCount":96},[],{"trials":1145,"activeCount":96},[],{"trials":1147,"activeCount":112,"soonestReadout":164},[1148],{"nctId":161,"briefTitle":162,"status":100,"phases":1149,"primaryCompletion":164,"completion":165,"start":166,"enrollment":167,"conditions":1150,"interventions":1151},[86],[30],[170,92],{"trials":1153,"activeCount":96},[],{"trials":1155,"activeCount":96},[],{"trials":1157,"activeCount":96},[],{"intervention":196,"totalTrials":22,"cells":1159},{"EARLY_PHASE1":1160,"PHASE1":1162,"PHASE2":1179,"PHASE3":1193,"PHASE4":1195,"NA":1197},{"trials":1161,"activeCount":96},[],{"trials":1163,"activeCount":112,"soonestReadout":120},[1164,1175],{"nctId":1165,"briefTitle":1166,"status":100,"phases":1167,"primaryCompletion":120,"completion":120,"start":1168,"enrollment":485,"conditions":1169,"interventions":1171},"NCT07004244","Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies",[85],"2025-06-05",[1170],"Malignant Tumors",[1172,1173,1174],"KRAS-mutated mRNA vaccine","TORIPALIMAB","Pemetrexed+carboplatin",{"nctId":186,"briefTitle":187,"status":188,"phases":1176,"primaryCompletion":190,"completion":191,"start":192,"enrollment":96,"conditions":1177,"interventions":1178},[85],[28],[195,196,197,178,198],{"trials":1180,"activeCount":96},[1181],{"nctId":1182,"briefTitle":1183,"status":222,"phases":1184,"primaryCompletion":1185,"completion":1186,"start":1187,"enrollment":1188,"conditions":1189,"interventions":1191},"NCT04337463","ATG-008 Combined With Toripalimab in Advanced Solid Tumors",[85,86],"2022-05-01","2022-12-01","2020-04-23",60,[1190],"Advanced Solid Tumor",[1192,196],"ATG-008",{"trials":1194,"activeCount":96},[],{"trials":1196,"activeCount":96},[],{"trials":1198,"activeCount":96},[],{"intervention":1200,"totalTrials":112,"cells":1201},"α-PD-L1\u002F4-1BB DLL3 CAR-T",{"EARLY_PHASE1":1202,"PHASE1":1204,"PHASE2":1214,"PHASE3":1216,"PHASE4":1218,"NA":1220},{"trials":1203,"activeCount":96},[],{"trials":1205,"activeCount":112,"soonestReadout":1210},[1206],{"nctId":1207,"briefTitle":1208,"status":100,"phases":1209,"primaryCompletion":1210,"completion":102,"start":1211,"enrollment":800,"conditions":1212,"interventions":1213},"NCT06348797","Phase I Clinical Study of α-PD-L1\u002FDLL3 CAR-T in Patients With R\u002FR SCLC",[85],"2026-06-30","2025-04-03",[30],[1200],{"trials":1215,"activeCount":96},[],{"trials":1217,"activeCount":96},[],{"trials":1219,"activeCount":96},[],{"trials":1221,"activeCount":96},[],{"intervention":1223,"totalTrials":112,"cells":1224},"Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy",{"EARLY_PHASE1":1225,"PHASE1":1227,"PHASE2":1238,"PHASE3":1240,"PHASE4":1242,"NA":1244},{"trials":1226,"activeCount":96},[],{"trials":1228,"activeCount":112,"soonestReadout":1007},[1229],{"nctId":1230,"briefTitle":1231,"status":100,"phases":1232,"primaryCompletion":1007,"completion":1233,"start":1234,"enrollment":1235,"conditions":1236,"interventions":1237},"NCT06344156","Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer",[85],"2027-04-01","2024-04-01",43,[33,135],[1223],{"trials":1239,"activeCount":96},[],{"trials":1241,"activeCount":96},[],{"trials":1243,"activeCount":96},[],{"trials":1245,"activeCount":96},[],{"intervention":44,"totalTrials":112,"cells":1247},{"EARLY_PHASE1":1248,"PHASE1":1250,"PHASE2":1259,"PHASE3":1261,"PHASE4":1263,"NA":1265},{"trials":1249,"activeCount":96},[],{"trials":1251,"activeCount":112,"soonestReadout":43},[1252],{"nctId":41,"briefTitle":42,"status":202,"phases":1253,"primaryCompletion":43,"completion":102,"start":1254,"enrollment":1255,"conditions":1256,"interventions":1258},[85],"2021-12-15",9,[106,107,1257,108],"Stereotactic Body Radiotherapy",[44],{"trials":1260,"activeCount":96},[],{"trials":1262,"activeCount":96},[],{"trials":1264,"activeCount":96},[],{"trials":1266,"activeCount":96},[],{"intervention":1268,"totalTrials":112,"cells":1269},"DC vaccine subcutaneous administration",{"EARLY_PHASE1":1270,"PHASE1":1272,"PHASE2":1285,"PHASE3":1287,"PHASE4":1289,"NA":1291},{"trials":1271,"activeCount":96},[],{"trials":1273,"activeCount":112,"soonestReadout":225},[1274],{"nctId":1275,"briefTitle":1276,"status":100,"phases":1277,"primaryCompletion":225,"completion":1278,"start":1279,"enrollment":238,"conditions":1280,"interventions":1284},"NCT04147078","Personalized DC Vaccine for Postoperative Cancer",[85],"2026-06-01","2019-06-01",[18,1281,1282,1283],"Hepatocellular Carcinoma","Non-Small-Cell Lung Cancer","Colon Rectal Cancer",[1268],{"trials":1286,"activeCount":96},[],{"trials":1288,"activeCount":96},[],{"trials":1290,"activeCount":96},[],{"trials":1292,"activeCount":96},[],{"intervention":1294,"totalTrials":112,"cells":1295},"Oncolytic virus Plus Anti-PD1 and Chemotherapy",{"EARLY_PHASE1":1296,"PHASE1":1298,"PHASE2":1309,"PHASE3":1311,"PHASE4":1313,"NA":1315},{"trials":1297,"activeCount":96},[],{"trials":1299,"activeCount":112,"soonestReadout":1304},[1300],{"nctId":1301,"briefTitle":1302,"status":118,"phases":1303,"primaryCompletion":1304,"completion":1305,"start":1306,"enrollment":485,"conditions":1307,"interventions":1308},"NCT06346808","Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC\u002FLAPC",[85],"2026-05-01","2027-05-01","2024-05-01",[33],[1294],{"trials":1310,"activeCount":96},[],{"trials":1312,"activeCount":96},[],{"trials":1314,"activeCount":96},[],{"trials":1316,"activeCount":96},[],{"intervention":1172,"totalTrials":112,"cells":1318},{"EARLY_PHASE1":1319,"PHASE1":1321,"PHASE2":1327,"PHASE3":1329,"PHASE4":1331,"NA":1333},{"trials":1320,"activeCount":96},[],{"trials":1322,"activeCount":112,"soonestReadout":120},[1323],{"nctId":1165,"briefTitle":1166,"status":100,"phases":1324,"primaryCompletion":120,"completion":120,"start":1168,"enrollment":485,"conditions":1325,"interventions":1326},[85],[1170],[1172,1173,1174],{"trials":1328,"activeCount":96},[],{"trials":1330,"activeCount":96},[],{"trials":1332,"activeCount":96},[],{"trials":1334,"activeCount":96},[],{"intervention":1174,"totalTrials":112,"cells":1336},{"EARLY_PHASE1":1337,"PHASE1":1339,"PHASE2":1345,"PHASE3":1347,"PHASE4":1349,"NA":1351},{"trials":1338,"activeCount":96},[],{"trials":1340,"activeCount":112,"soonestReadout":120},[1341],{"nctId":1165,"briefTitle":1166,"status":100,"phases":1342,"primaryCompletion":120,"completion":120,"start":1168,"enrollment":485,"conditions":1343,"interventions":1344},[85],[1170],[1172,1173,1174],{"trials":1346,"activeCount":96},[],{"trials":1348,"activeCount":96},[],{"trials":1350,"activeCount":96},[],{"trials":1352,"activeCount":96},[],{"intervention":67,"totalTrials":112,"cells":1354},{"EARLY_PHASE1":1355,"PHASE1":1357,"PHASE2":1363,"PHASE3":1365,"PHASE4":1367,"NA":1369},{"trials":1356,"activeCount":96},[],{"trials":1358,"activeCount":112,"soonestReadout":66},[1359],{"nctId":64,"briefTitle":65,"status":100,"phases":1360,"primaryCompletion":66,"completion":102,"start":103,"enrollment":104,"conditions":1361,"interventions":1362},[85],[106,107,108,109],[67,111,92],{"trials":1364,"activeCount":96},[],{"trials":1366,"activeCount":96},[],{"trials":1368,"activeCount":96},[],{"trials":1370,"activeCount":96},[],{"intervention":1372,"totalTrials":112,"cells":1373},"Dual-targeting CLDN18.2 and PD-L1 CAR-T cells",{"EARLY_PHASE1":1374,"PHASE1":1376,"PHASE2":1386,"PHASE3":1388,"PHASE4":1390,"NA":1392},{"trials":1375,"activeCount":96},[],{"trials":1377,"activeCount":112,"soonestReadout":1382},[1378],{"nctId":1379,"briefTitle":1380,"status":100,"phases":1381,"primaryCompletion":1382,"completion":1382,"start":1383,"enrollment":348,"conditions":1384,"interventions":1385},"NCT06084286","Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors",[85],"2026-10-30","2024-01-01",[1190],[1372],{"trials":1387,"activeCount":96},[],{"trials":1389,"activeCount":96},[],{"trials":1391,"activeCount":96},[],{"trials":1393,"activeCount":96},[],{"intervention":1395,"totalTrials":112,"cells":1396},"recombinant human endostatin adenovirus",{"EARLY_PHASE1":1397,"PHASE1":1399,"PHASE2":1409,"PHASE3":1411,"PHASE4":1413,"NA":1415},{"trials":1398,"activeCount":96},[],{"trials":1400,"activeCount":112,"soonestReadout":908},[1401],{"nctId":1402,"briefTitle":1403,"status":118,"phases":1404,"primaryCompletion":908,"completion":908,"start":1405,"enrollment":145,"conditions":1406,"interventions":1408},"NCT07154108","Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer",[85],"2025-09-01",[15,1407],"Head and Neck Cancer (H&Amp;Amp;Amp;N)",[1395,108],{"trials":1410,"activeCount":96},[],{"trials":1412,"activeCount":96},[],{"trials":1414,"activeCount":96},[],{"trials":1416,"activeCount":96},[],{"intervention":108,"totalTrials":112,"cells":1418},{"EARLY_PHASE1":1419,"PHASE1":1421,"PHASE2":1427,"PHASE3":1429,"PHASE4":1431,"NA":1433},{"trials":1420,"activeCount":96},[],{"trials":1422,"activeCount":112,"soonestReadout":908},[1423],{"nctId":1402,"briefTitle":1403,"status":118,"phases":1424,"primaryCompletion":908,"completion":908,"start":1405,"enrollment":145,"conditions":1425,"interventions":1426},[85],[15,1407],[1395,108],{"trials":1428,"activeCount":96},[],{"trials":1430,"activeCount":96},[],{"trials":1432,"activeCount":96},[],{"trials":1434,"activeCount":96},[],{"intervention":1436,"totalTrials":112,"cells":1437},"WGb-0301",{"EARLY_PHASE1":1438,"PHASE1":1448,"PHASE2":1450,"PHASE3":1452,"PHASE4":1454,"NA":1456},{"trials":1439,"activeCount":112,"soonestReadout":120},[1440],{"nctId":1441,"briefTitle":1442,"status":118,"phases":1443,"primaryCompletion":120,"completion":1006,"start":1444,"enrollment":1255,"conditions":1445,"interventions":1447},"NCT07332663","Exploratory Study on the Treatment of Relapsed and Refractory B-cell Malignant Tumors With WGb-0301 Injection",[84],"2026-01-01",[1446],"B Cell Malignancies",[1436],{"trials":1449,"activeCount":96},[],{"trials":1451,"activeCount":96},[],{"trials":1453,"activeCount":96},[],{"trials":1455,"activeCount":96},[],{"trials":1457,"activeCount":96},[],{"intervention":1459,"totalTrials":112,"cells":1460},"WGb-0302",{"EARLY_PHASE1":1461,"PHASE1":1470,"PHASE2":1472,"PHASE3":1474,"PHASE4":1476,"NA":1478},{"trials":1462,"activeCount":112,"soonestReadout":120},[1463],{"nctId":1464,"briefTitle":1465,"status":118,"phases":1466,"primaryCompletion":120,"completion":1006,"start":512,"enrollment":485,"conditions":1467,"interventions":1469},"NCT07362732","Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection",[84],[1468],"Hematological Malignancies",[1459],{"trials":1471,"activeCount":96},[],{"trials":1473,"activeCount":96},[],{"trials":1475,"activeCount":96},[],{"trials":1477,"activeCount":96},[],{"trials":1479,"activeCount":96},[],{"intervention":1481,"totalTrials":112,"cells":1482},"IR-101",{"EARLY_PHASE1":1483,"PHASE1":1493,"PHASE2":1495,"PHASE3":1497,"PHASE4":1499,"NA":1501},{"trials":1484,"activeCount":112,"soonestReadout":1210},[1485],{"nctId":1486,"briefTitle":1487,"status":100,"phases":1488,"primaryCompletion":1210,"completion":1210,"start":1489,"enrollment":104,"conditions":1490,"interventions":1492},"NCT07067346","Safety & Efficacy of IR-101 in Relapsed\u002FRefractory Neuroblastoma",[84],"2025-07-18",[1491],"Neuroblastoma",[1481],{"trials":1494,"activeCount":96},[],{"trials":1496,"activeCount":96},[],{"trials":1498,"activeCount":96},[],{"trials":1500,"activeCount":96},[],{"trials":1502,"activeCount":96},[],{"intervention":1504,"totalTrials":112,"cells":1505},"Dual-targeting HER2 and PD-L1 CAR-T cells",{"EARLY_PHASE1":1506,"PHASE1":1519,"PHASE2":1521,"PHASE3":1523,"PHASE4":1525,"NA":1527},{"trials":1507,"activeCount":112,"soonestReadout":317},[1508],{"nctId":1509,"briefTitle":1510,"status":100,"phases":1511,"primaryCompletion":317,"completion":317,"start":1512,"enrollment":1513,"conditions":1514,"interventions":1518},"NCT04684459","Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors",[84],"2021-03-12",18,[1515,1516,1517],"Peritoneal Carcinoma Metastatic","Pleural Effusion, Malignant","HER2 Positive Malignancies",[1504],{"trials":1520,"activeCount":96},[],{"trials":1522,"activeCount":96},[],{"trials":1524,"activeCount":96},[],{"trials":1526,"activeCount":96},[],{"trials":1528,"activeCount":96},[],{"intervention":1530,"totalTrials":112,"cells":1531},"Immune Checkpoint Inhibitors",{"EARLY_PHASE1":1532,"PHASE1":1534,"PHASE2":1536,"PHASE3":1538,"PHASE4":1540,"NA":1542},{"trials":1533,"activeCount":96},[],{"trials":1535,"activeCount":96},[],{"trials":1537,"activeCount":96},[],{"trials":1539,"activeCount":96},[],{"trials":1541,"activeCount":96},[],{"trials":1543,"activeCount":112,"soonestReadout":102},[1544],{"nctId":1545,"briefTitle":1546,"status":118,"phases":1547,"primaryCompletion":102,"completion":102,"start":1548,"enrollment":1549,"conditions":1550,"interventions":1551},"NCT07067450","Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma",[89],"2025-07-20",98,[21],[1530],{"intervention":270,"totalTrials":9,"cells":1553},{"EARLY_PHASE1":1554,"PHASE1":1556,"PHASE2":1558,"PHASE3":1568,"PHASE4":1574,"NA":1580},{"trials":1555,"activeCount":96},[],{"trials":1557,"activeCount":96},[],{"trials":1559,"activeCount":96},[1560,1564],{"nctId":602,"briefTitle":603,"status":222,"phases":1561,"primaryCompletion":573,"completion":574,"start":575,"enrollment":123,"conditions":1562,"interventions":1563},[86],[606,607],[39,324,270,326],{"nctId":610,"briefTitle":611,"status":222,"phases":1565,"primaryCompletion":613,"completion":614,"start":615,"enrollment":616,"conditions":1566,"interventions":1567},[86],[618],[39,324,270,326],{"trials":1569,"activeCount":96},[1570],{"nctId":314,"briefTitle":315,"status":222,"phases":1571,"primaryCompletion":317,"completion":317,"start":318,"enrollment":319,"conditions":1572,"interventions":1573},[87],[321,322],[39,324,325,326,327,198,328,329],{"trials":1575,"activeCount":96},[1576],{"nctId":259,"briefTitle":260,"status":261,"phases":1577,"primaryCompletion":263,"completion":263,"start":264,"enrollment":205,"conditions":1578,"interventions":1579},[88],[266,267],[269,270,271],{"trials":1581,"activeCount":96},[],{"intervention":1583,"totalTrials":112,"cells":1584},"Quetiapine fumarate",{"EARLY_PHASE1":1585,"PHASE1":1587,"PHASE2":1589,"PHASE3":1591,"PHASE4":1593,"NA":1606},{"trials":1586,"activeCount":96},[],{"trials":1588,"activeCount":96},[],{"trials":1590,"activeCount":96},[],{"trials":1592,"activeCount":96},[],{"trials":1594,"activeCount":96},[1595],{"nctId":1596,"briefTitle":1597,"status":222,"phases":1598,"primaryCompletion":1599,"completion":1599,"start":1600,"enrollment":1601,"conditions":1602,"interventions":1604},"NCT00838032","Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia",[88],"2010-05","2008-08",70,[1603],"Acute Schizophrenia",[1583,1605],"Haloperidol",{"trials":1607,"activeCount":96},[],{"intervention":1605,"totalTrials":112,"cells":1609},{"EARLY_PHASE1":1610,"PHASE1":1612,"PHASE2":1614,"PHASE3":1616,"PHASE4":1618,"NA":1624},{"trials":1611,"activeCount":96},[],{"trials":1613,"activeCount":96},[],{"trials":1615,"activeCount":96},[],{"trials":1617,"activeCount":96},[],{"trials":1619,"activeCount":96},[1620],{"nctId":1596,"briefTitle":1597,"status":222,"phases":1621,"primaryCompletion":1599,"completion":1599,"start":1600,"enrollment":1601,"conditions":1622,"interventions":1623},[88],[1603],[1583,1605],{"trials":1625,"activeCount":96},[],{"intervention":269,"totalTrials":112,"cells":1627},{"EARLY_PHASE1":1628,"PHASE1":1630,"PHASE2":1632,"PHASE3":1634,"PHASE4":1636,"NA":1642},{"trials":1629,"activeCount":96},[],{"trials":1631,"activeCount":96},[],{"trials":1633,"activeCount":96},[],{"trials":1635,"activeCount":96},[],{"trials":1637,"activeCount":96},[1638],{"nctId":259,"briefTitle":260,"status":261,"phases":1639,"primaryCompletion":263,"completion":263,"start":264,"enrollment":205,"conditions":1640,"interventions":1641},[88],[266,267],[269,270,271],{"trials":1643,"activeCount":96},[],{"intervention":324,"totalTrials":22,"cells":1645},{"EARLY_PHASE1":1646,"PHASE1":1648,"PHASE2":1650,"PHASE3":1660,"PHASE4":1666,"NA":1668},{"trials":1647,"activeCount":96},[],{"trials":1649,"activeCount":96},[],{"trials":1651,"activeCount":96},[1652,1656],{"nctId":602,"briefTitle":603,"status":222,"phases":1653,"primaryCompletion":573,"completion":574,"start":575,"enrollment":123,"conditions":1654,"interventions":1655},[86],[606,607],[39,324,270,326],{"nctId":610,"briefTitle":611,"status":222,"phases":1657,"primaryCompletion":613,"completion":614,"start":615,"enrollment":616,"conditions":1658,"interventions":1659},[86],[618],[39,324,270,326],{"trials":1661,"activeCount":96},[1662],{"nctId":314,"briefTitle":315,"status":222,"phases":1663,"primaryCompletion":317,"completion":317,"start":318,"enrollment":319,"conditions":1664,"interventions":1665},[87],[321,322],[39,324,325,326,327,198,328,329],{"trials":1667,"activeCount":96},[],{"trials":1669,"activeCount":96},[],{"intervention":326,"totalTrials":22,"cells":1671},{"EARLY_PHASE1":1672,"PHASE1":1674,"PHASE2":1676,"PHASE3":1686,"PHASE4":1692,"NA":1694},{"trials":1673,"activeCount":96},[],{"trials":1675,"activeCount":96},[],{"trials":1677,"activeCount":96},[1678,1682],{"nctId":602,"briefTitle":603,"status":222,"phases":1679,"primaryCompletion":573,"completion":574,"start":575,"enrollment":123,"conditions":1680,"interventions":1681},[86],[606,607],[39,324,270,326],{"nctId":610,"briefTitle":611,"status":222,"phases":1683,"primaryCompletion":613,"completion":614,"start":615,"enrollment":616,"conditions":1684,"interventions":1685},[86],[618],[39,324,270,326],{"trials":1687,"activeCount":96},[1688],{"nctId":314,"briefTitle":315,"status":222,"phases":1689,"primaryCompletion":317,"completion":317,"start":318,"enrollment":319,"conditions":1690,"interventions":1691},[87],[321,322],[39,324,325,326,327,198,328,329],{"trials":1693,"activeCount":96},[],{"trials":1695,"activeCount":96},[],{"intervention":1697,"totalTrials":112,"cells":1698},"100 ml lactulose combined with 1 L PEG",{"EARLY_PHASE1":1699,"PHASE1":1701,"PHASE2":1703,"PHASE3":1705,"PHASE4":1720,"NA":1722},{"trials":1700,"activeCount":96},[],{"trials":1702,"activeCount":96},[],{"trials":1704,"activeCount":96},[],{"trials":1706,"activeCount":96},[1707],{"nctId":1708,"briefTitle":1709,"status":343,"phases":1710,"primaryCompletion":1711,"completion":1711,"start":1712,"enrollment":1713,"conditions":1714,"interventions":1716},"NCT05076799","Effect of Lactulose and\u002For Polyethylene Glycol Solution for Bowel Preparation for Colonscopy Procedures",[87],"2022-11-30","2021-09-01",200,[1715],"Colonoscopy",[1697,1717,1718,1719],"100 ml lactulose combined with 2 L PEG","200 ml lactulose","3 L Polyethylene glycol solution",{"trials":1721,"activeCount":96},[],{"trials":1723,"activeCount":96},[],{"intervention":1717,"totalTrials":112,"cells":1725},{"EARLY_PHASE1":1726,"PHASE1":1728,"PHASE2":1730,"PHASE3":1732,"PHASE4":1738,"NA":1740},{"trials":1727,"activeCount":96},[],{"trials":1729,"activeCount":96},[],{"trials":1731,"activeCount":96},[],{"trials":1733,"activeCount":96},[1734],{"nctId":1708,"briefTitle":1709,"status":343,"phases":1735,"primaryCompletion":1711,"completion":1711,"start":1712,"enrollment":1713,"conditions":1736,"interventions":1737},[87],[1715],[1697,1717,1718,1719],{"trials":1739,"activeCount":96},[],{"trials":1741,"activeCount":96},[],{"intervention":1718,"totalTrials":112,"cells":1743},{"EARLY_PHASE1":1744,"PHASE1":1746,"PHASE2":1748,"PHASE3":1750,"PHASE4":1756,"NA":1758},{"trials":1745,"activeCount":96},[],{"trials":1747,"activeCount":96},[],{"trials":1749,"activeCount":96},[],{"trials":1751,"activeCount":96},[1752],{"nctId":1708,"briefTitle":1709,"status":343,"phases":1753,"primaryCompletion":1711,"completion":1711,"start":1712,"enrollment":1713,"conditions":1754,"interventions":1755},[87],[1715],[1697,1717,1718,1719],{"trials":1757,"activeCount":96},[],{"trials":1759,"activeCount":96},[],{"intervention":1719,"totalTrials":112,"cells":1761},{"EARLY_PHASE1":1762,"PHASE1":1764,"PHASE2":1766,"PHASE3":1768,"PHASE4":1774,"NA":1776},{"trials":1763,"activeCount":96},[],{"trials":1765,"activeCount":96},[],{"trials":1767,"activeCount":96},[],{"trials":1769,"activeCount":96},[1770],{"nctId":1708,"briefTitle":1709,"status":343,"phases":1771,"primaryCompletion":1711,"completion":1711,"start":1712,"enrollment":1713,"conditions":1772,"interventions":1773},[87],[1715],[1697,1717,1718,1719],{"trials":1775,"activeCount":96},[],{"trials":1777,"activeCount":96},[],{"intervention":327,"totalTrials":112,"cells":1779},{"EARLY_PHASE1":1780,"PHASE1":1782,"PHASE2":1784,"PHASE3":1786,"PHASE4":1792,"NA":1794},{"trials":1781,"activeCount":96},[],{"trials":1783,"activeCount":96},[],{"trials":1785,"activeCount":96},[],{"trials":1787,"activeCount":96},[1788],{"nctId":314,"briefTitle":315,"status":222,"phases":1789,"primaryCompletion":317,"completion":317,"start":318,"enrollment":319,"conditions":1790,"interventions":1791},[87],[321,322],[39,324,325,326,327,198,328,329],{"trials":1793,"activeCount":96},[],{"trials":1795,"activeCount":96},[],{"intervention":328,"totalTrials":112,"cells":1797},{"EARLY_PHASE1":1798,"PHASE1":1800,"PHASE2":1802,"PHASE3":1804,"PHASE4":1810,"NA":1812},{"trials":1799,"activeCount":96},[],{"trials":1801,"activeCount":96},[],{"trials":1803,"activeCount":96},[],{"trials":1805,"activeCount":96},[1806],{"nctId":314,"briefTitle":315,"status":222,"phases":1807,"primaryCompletion":317,"completion":317,"start":318,"enrollment":319,"conditions":1808,"interventions":1809},[87],[321,322],[39,324,325,326,327,198,328,329],{"trials":1811,"activeCount":96},[],{"trials":1813,"activeCount":96},[],{"intervention":329,"totalTrials":112,"cells":1815},{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1820,"PHASE3":1822,"PHASE4":1828,"NA":1830},{"trials":1817,"activeCount":96},[],{"trials":1819,"activeCount":96},[],{"trials":1821,"activeCount":96},[],{"trials":1823,"activeCount":96},[1824],{"nctId":314,"briefTitle":315,"status":222,"phases":1825,"primaryCompletion":317,"completion":317,"start":318,"enrollment":319,"conditions":1826,"interventions":1827},[87],[321,322],[39,324,325,326,327,198,328,329],{"trials":1829,"activeCount":96},[],{"trials":1831,"activeCount":96},[],{"intervention":581,"totalTrials":31,"cells":1833},{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1848,"PHASE3":1854,"PHASE4":1856,"NA":1858},{"trials":1835,"activeCount":96},[],{"trials":1837,"activeCount":96},[1838],{"nctId":1839,"briefTitle":1840,"status":343,"phases":1841,"primaryCompletion":1842,"completion":1843,"start":1844,"enrollment":650,"conditions":1845,"interventions":1847},"NCT02793856","PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer",[85],"2018-08-20","2020-03-17","2016-08-26",[1846],"Metastatic Non-small Cell Lung Cancer",[581],{"trials":1849,"activeCount":96},[1850],{"nctId":570,"briefTitle":571,"status":222,"phases":1851,"primaryCompletion":573,"completion":574,"start":575,"enrollment":576,"conditions":1852,"interventions":1853},[86],[578,579],[39,581,582],{"trials":1855,"activeCount":96},[],{"trials":1857,"activeCount":96},[],{"trials":1859,"activeCount":96},[],{"intervention":1861,"totalTrials":112,"cells":1862},"GLIDE",{"EARLY_PHASE1":1863,"PHASE1":1865,"PHASE2":1867,"PHASE3":1878,"PHASE4":1880,"NA":1882},{"trials":1864,"activeCount":96},[],{"trials":1866,"activeCount":96},[],{"trials":1868,"activeCount":96},[1869],{"nctId":1870,"briefTitle":1871,"status":222,"phases":1872,"primaryCompletion":1873,"completion":574,"start":1874,"enrollment":1188,"conditions":1875,"interventions":1877},"NCT03154918","GLIDE Regimen Followed by ASCT for Aggressive NK\u002FT Cell Lymphoma",[86],"2020-12-31","2017-06-01",[1876],"Lymphoma, Extranodal NK-T-Cell",[1861],{"trials":1879,"activeCount":96},[],{"trials":1881,"activeCount":96},[],{"trials":1883,"activeCount":96},[],{"intervention":1885,"totalTrials":112,"cells":1886},"sorafenib; toripalimab",{"EARLY_PHASE1":1887,"PHASE1":1889,"PHASE2":1891,"PHASE3":1905,"PHASE4":1907,"NA":1909},{"trials":1888,"activeCount":96},[],{"trials":1890,"activeCount":96},[],{"trials":1892,"activeCount":96},[1893],{"nctId":1894,"briefTitle":1895,"status":222,"phases":1896,"primaryCompletion":1897,"completion":1898,"start":1899,"enrollment":1900,"conditions":1901,"interventions":1904},"NCT04069949","Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus",[85,86],"2020-10-01","2021-10-01","2019-12-01",39,[1902,1903],"Unresectable Hepatocellular Cancer","Portal Vein Tumor Thrombus",[1885],{"trials":1906,"activeCount":96},[],{"trials":1908,"activeCount":96},[],{"trials":1910,"activeCount":96},[],{"intervention":1912,"totalTrials":112,"cells":1913},"Methylprednisolone",{"EARLY_PHASE1":1914,"PHASE1":1916,"PHASE2":1918,"PHASE3":1931,"PHASE4":1933,"NA":1935},{"trials":1915,"activeCount":96},[],{"trials":1917,"activeCount":96},[],{"trials":1919,"activeCount":96},[1920],{"nctId":1921,"briefTitle":1922,"status":222,"phases":1923,"primaryCompletion":1924,"completion":1925,"start":1185,"enrollment":1926,"conditions":1927,"interventions":1930},"NCT05368181","MAP-guided Preemptive Therapy of aGvHD",[86],"2023-01-30","2024-12-31",56,[1928,1929],"GVHD,Acute","Stem Cell Transplant Complications",[1912],{"trials":1932,"activeCount":96},[],{"trials":1934,"activeCount":96},[],{"trials":1936,"activeCount":96},[],{"intervention":582,"totalTrials":112,"cells":1938},{"EARLY_PHASE1":1939,"PHASE1":1941,"PHASE2":1943,"PHASE3":1949,"PHASE4":1951,"NA":1953},{"trials":1940,"activeCount":96},[],{"trials":1942,"activeCount":96},[],{"trials":1944,"activeCount":96},[1945],{"nctId":570,"briefTitle":571,"status":222,"phases":1946,"primaryCompletion":573,"completion":574,"start":575,"enrollment":576,"conditions":1947,"interventions":1948},[86],[578,579],[39,581,582],{"trials":1950,"activeCount":96},[],{"trials":1952,"activeCount":96},[],{"trials":1954,"activeCount":96},[],{"intervention":592,"totalTrials":112,"cells":1956},{"EARLY_PHASE1":1957,"PHASE1":1959,"PHASE2":1961,"PHASE3":1967,"PHASE4":1969,"NA":1971},{"trials":1958,"activeCount":96},[],{"trials":1960,"activeCount":96},[],{"trials":1962,"activeCount":96},[1963],{"nctId":584,"briefTitle":585,"status":222,"phases":1964,"primaryCompletion":587,"completion":588,"start":575,"enrollment":485,"conditions":1965,"interventions":1966},[86],[590],[592,593],{"trials":1968,"activeCount":96},[],{"trials":1970,"activeCount":96},[],{"trials":1972,"activeCount":96},[],{"intervention":1974,"totalTrials":112,"cells":1975},"Fruquintinib",{"EARLY_PHASE1":1976,"PHASE1":1978,"PHASE2":1980,"PHASE3":1990,"PHASE4":1992,"NA":1994},{"trials":1977,"activeCount":96},[],{"trials":1979,"activeCount":96},[],{"trials":1981,"activeCount":96},[1982],{"nctId":1983,"briefTitle":1984,"status":222,"phases":1985,"primaryCompletion":1986,"completion":614,"start":466,"enrollment":1008,"conditions":1987,"interventions":1989},"NCT04156958","Fruquintinib as Second-line Treatment for Advanced\u002FMetastatic Biliary Tract Adenocarcinoma",[86],"2021-09",[1988],"Biliary Tract Adenocarcinoma",[1974],{"trials":1991,"activeCount":96},[],{"trials":1993,"activeCount":96},[],{"trials":1995,"activeCount":96},[],{"intervention":1997,"totalTrials":112,"cells":1998},"fractionated busulfan-based conditioning regimen",{"EARLY_PHASE1":1999,"PHASE1":2001,"PHASE2":2003,"PHASE3":2014,"PHASE4":2016,"NA":2018},{"trials":2000,"activeCount":96},[],{"trials":2002,"activeCount":96},[],{"trials":2004,"activeCount":96},[2005],{"nctId":2006,"briefTitle":2007,"status":222,"phases":2008,"primaryCompletion":2009,"completion":225,"start":2010,"enrollment":1513,"conditions":2011,"interventions":2013},"NCT05807659","Fractionated Busulfan Conditioning Regimen for Allo-HSCT in Non-remission Myeloid Malignancies",[86],"2025-08-31","2023-03-16",[2012],"Myeloid Malignancies",[1997],{"trials":2015,"activeCount":96},[],{"trials":2017,"activeCount":96},[],{"trials":2019,"activeCount":96},[],{"intervention":2021,"totalTrials":112,"cells":2022},"S-1, Oxaliplatin, Cadonilimab",{"EARLY_PHASE1":2023,"PHASE1":2025,"PHASE2":2027,"PHASE3":2039,"PHASE4":2041,"NA":2043},{"trials":2024,"activeCount":96},[],{"trials":2026,"activeCount":96},[],{"trials":2028,"activeCount":96},[2029],{"nctId":2030,"briefTitle":2031,"status":222,"phases":2032,"primaryCompletion":2033,"completion":2034,"start":2035,"enrollment":2036,"conditions":2037,"interventions":2038},"NCT05948449","To Evaluate the Efficacy and Safety of Cadonilimab With SOX as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.",[86],"2025-01","2025-07","2023-07",37,[18],[2021],{"trials":2040,"activeCount":96},[],{"trials":2042,"activeCount":96},[],{"trials":2044,"activeCount":96},[],{"intervention":654,"totalTrials":112,"cells":2046},{"EARLY_PHASE1":2047,"PHASE1":2049,"PHASE2":2051,"PHASE3":2057,"PHASE4":2059,"NA":2061},{"trials":2048,"activeCount":96},[],{"trials":2050,"activeCount":96},[],{"trials":2052,"activeCount":96},[2053],{"nctId":646,"briefTitle":647,"status":222,"phases":2054,"primaryCompletion":573,"completion":574,"start":649,"enrollment":650,"conditions":2055,"interventions":2056},[85,86],[652],[59,654,655],{"trials":2058,"activeCount":96},[],{"trials":2060,"activeCount":96},[],{"trials":2062,"activeCount":96},[],{"intervention":655,"totalTrials":112,"cells":2064},{"EARLY_PHASE1":2065,"PHASE1":2067,"PHASE2":2069,"PHASE3":2075,"PHASE4":2077,"NA":2079},{"trials":2066,"activeCount":96},[],{"trials":2068,"activeCount":96},[],{"trials":2070,"activeCount":96},[2071],{"nctId":646,"briefTitle":647,"status":222,"phases":2072,"primaryCompletion":573,"completion":574,"start":649,"enrollment":650,"conditions":2073,"interventions":2074},[85,86],[652],[59,654,655],{"trials":2076,"activeCount":96},[],{"trials":2078,"activeCount":96},[],{"trials":2080,"activeCount":96},[],{"intervention":231,"totalTrials":112,"cells":2082},{"EARLY_PHASE1":2083,"PHASE1":2085,"PHASE2":2087,"PHASE3":2093,"PHASE4":2095,"NA":2097},{"trials":2084,"activeCount":96},[],{"trials":2086,"activeCount":96},[],{"trials":2088,"activeCount":96},[2089],{"nctId":220,"briefTitle":221,"status":222,"phases":2090,"primaryCompletion":224,"completion":225,"start":226,"enrollment":227,"conditions":2091,"interventions":2092},[86],[229],[231,178,232,72],{"trials":2094,"activeCount":96},[],{"trials":2096,"activeCount":96},[],{"trials":2098,"activeCount":96},[],{"intervention":232,"totalTrials":112,"cells":2100},{"EARLY_PHASE1":2101,"PHASE1":2103,"PHASE2":2105,"PHASE3":2111,"PHASE4":2113,"NA":2115},{"trials":2102,"activeCount":96},[],{"trials":2104,"activeCount":96},[],{"trials":2106,"activeCount":96},[2107],{"nctId":220,"briefTitle":221,"status":222,"phases":2108,"primaryCompletion":224,"completion":225,"start":226,"enrollment":227,"conditions":2109,"interventions":2110},[86],[229],[231,178,232,72],{"trials":2112,"activeCount":96},[],{"trials":2114,"activeCount":96},[],{"trials":2116,"activeCount":96},[],{"intervention":1192,"totalTrials":112,"cells":2118},{"EARLY_PHASE1":2119,"PHASE1":2121,"PHASE2":2123,"PHASE3":2129,"PHASE4":2131,"NA":2133},{"trials":2120,"activeCount":96},[],{"trials":2122,"activeCount":96},[],{"trials":2124,"activeCount":96},[2125],{"nctId":1182,"briefTitle":1183,"status":222,"phases":2126,"primaryCompletion":1185,"completion":1186,"start":1187,"enrollment":1188,"conditions":2127,"interventions":2128},[85,86],[1190],[1192,196],{"trials":2130,"activeCount":96},[],{"trials":2132,"activeCount":96},[],{"trials":2134,"activeCount":96},[],{"intervention":2136,"totalTrials":112,"cells":2137},"camrelizumab\u002Flenvatinib combined with TACE",{"EARLY_PHASE1":2138,"PHASE1":2140,"PHASE2":2142,"PHASE3":2154,"PHASE4":2156,"NA":2158},{"trials":2139,"activeCount":96},[],{"trials":2141,"activeCount":96},[],{"trials":2143,"activeCount":96},[2144],{"nctId":2145,"briefTitle":2146,"status":222,"phases":2147,"primaryCompletion":2148,"completion":546,"start":1712,"enrollment":2149,"conditions":2150,"interventions":2153},"NCT05042336","The Effectiveness and Safety of Camrelizumab\u002FLenvatinib Combined With TACE in Patients With Borderline Resectable HCC",[85,86],"2023-06-01",49,[2151,2152],"Carrelizumab Plus Lenvatinib Combined With TACE","Borderline Resectable Hepatocellular Carcinoma",[2136],{"trials":2155,"activeCount":96},[],{"trials":2157,"activeCount":96},[],{"trials":2159,"activeCount":96},[],{"intervention":2161,"totalTrials":112,"cells":2162},"Death mesenchymal stem cell",{"EARLY_PHASE1":2163,"PHASE1":2165,"PHASE2":2167,"PHASE3":2178,"PHASE4":2180,"NA":2182},{"trials":2164,"activeCount":96},[],{"trials":2166,"activeCount":96},[],{"trials":2168,"activeCount":96},[2169],{"nctId":2170,"briefTitle":2171,"status":222,"phases":2172,"primaryCompletion":2173,"completion":58,"start":540,"enrollment":2174,"conditions":2175,"interventions":2177},"NCT06021067","Dead Mesenchymal Stem Cells for Radiation Lung Injury",[85,86],"2024-09-10",15,[2176],"Radiation Lung Injury",[2161],{"trials":2179,"activeCount":96},[],{"trials":2181,"activeCount":96},[],{"trials":2183,"activeCount":96},[],{"intervention":2185,"totalTrials":112,"cells":2186},"Emulsified Isoflurane",{"EARLY_PHASE1":2187,"PHASE1":2189,"PHASE2":2200,"PHASE3":2202,"PHASE4":2204,"NA":2206},{"trials":2188,"activeCount":96},[],{"trials":2190,"activeCount":96},[2191],{"nctId":2192,"briefTitle":2193,"status":343,"phases":2194,"primaryCompletion":2195,"completion":2195,"start":1599,"enrollment":2196,"conditions":2197,"interventions":2199},"NCT01302353","Phase I Trial of Emulsified Isoflurane",[85],"2010-09",78,[2198],"Adverse Effect of Intravenous Anesthetics",[2185],{"trials":2201,"activeCount":96},[],{"trials":2203,"activeCount":96},[],{"trials":2205,"activeCount":96},[],{"trials":2207,"activeCount":96},[],{"intervention":2209,"totalTrials":112,"cells":2210},"CXCR4 modified anti-BCMA CAR T cells",{"EARLY_PHASE1":2211,"PHASE1":2213,"PHASE2":2223,"PHASE3":2225,"PHASE4":2227,"NA":2229},{"trials":2212,"activeCount":96},[],{"trials":2214,"activeCount":96},[2215],{"nctId":2216,"briefTitle":2217,"status":222,"phases":2218,"primaryCompletion":225,"completion":225,"start":2219,"enrollment":650,"conditions":2220,"interventions":2222},"NCT04727008","CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma",[85],"2022-09-21",[2221],"Multiple Myeloma",[2209],{"trials":2224,"activeCount":96},[],{"trials":2226,"activeCount":96},[],{"trials":2228,"activeCount":96},[],{"trials":2230,"activeCount":96},[],{"intervention":2232,"totalTrials":112,"cells":2233},"Tumor antigen-sensitized DC vaccine",{"EARLY_PHASE1":2234,"PHASE1":2236,"PHASE2":2247,"PHASE3":2249,"PHASE4":2251,"NA":2253},{"trials":2235,"activeCount":96},[],{"trials":2237,"activeCount":96},[2238],{"nctId":2239,"briefTitle":2240,"status":343,"phases":2241,"primaryCompletion":546,"completion":2242,"start":1712,"enrollment":717,"conditions":2243,"interventions":2246},"NCT05023928","Tumor Antigen-sensitized DC Vaccine As an Adjuvant Therapy for Esophagus Cancer",[85],"2024-10-30",[2244,2245],"Carcinoma","Esophagus Cancer",[2232],{"trials":2248,"activeCount":96},[],{"trials":2250,"activeCount":96},[],{"trials":2252,"activeCount":96},[],{"trials":2254,"activeCount":96},[],{"intervention":2256,"totalTrials":112,"cells":2257},"DC vaccine",{"EARLY_PHASE1":2258,"PHASE1":2260,"PHASE2":2271,"PHASE3":2273,"PHASE4":2275,"NA":2277},{"trials":2259,"activeCount":96},[],{"trials":2261,"activeCount":96},[2262],{"nctId":2263,"briefTitle":2264,"status":222,"phases":2265,"primaryCompletion":587,"completion":2266,"start":2267,"enrollment":485,"conditions":2268,"interventions":2270},"NCT02956551","Personalized DC Vaccine for Lung Cancer",[85],"2020-06-01","2016-11-30",[2269],"Carcinoma, Non-Small-Cell Lung",[2256],{"trials":2272,"activeCount":96},[],{"trials":2274,"activeCount":96},[],{"trials":2276,"activeCount":96},[],{"trials":2278,"activeCount":96},[],{"intervention":2280,"totalTrials":112,"cells":2281},"OCDC vaccine; NeoDC vaccine",{"EARLY_PHASE1":2282,"PHASE1":2284,"PHASE2":2294,"PHASE3":2296,"PHASE4":2298,"NA":2300},{"trials":2283,"activeCount":96},[],{"trials":2285,"activeCount":96},[2286],{"nctId":2287,"briefTitle":2288,"status":222,"phases":2289,"primaryCompletion":2290,"completion":1234,"start":2291,"enrollment":485,"conditions":2292,"interventions":2293},"NCT05317325","A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC",[85],"2023-12-30","2022-04-01",[26],[2280],{"trials":2295,"activeCount":96},[],{"trials":2297,"activeCount":96},[],{"trials":2299,"activeCount":96},[],{"trials":2301,"activeCount":96},[],{"intervention":2303,"totalTrials":112,"cells":2304},"EpCAM CAR-T cells",{"EARLY_PHASE1":2305,"PHASE1":2307,"PHASE2":2319,"PHASE3":2321,"PHASE4":2323,"NA":2325},{"trials":2306,"activeCount":96},[],{"trials":2308,"activeCount":96},[2309],{"nctId":2310,"briefTitle":2311,"status":222,"phases":2312,"primaryCompletion":2034,"completion":2034,"start":2313,"enrollment":123,"conditions":2314,"interventions":2318},"NCT02915445","EpCAM CAR-T for Treatment of Advanced Solid Tumors",[85],"2016-07",[2315,2316,2317],"Malignant Neoplasm of Nasopharynx TNM Staging Distant Metastasis (M)","Breast Cancer Recurrent","Gastric Cancer With Metastasis",[2303],{"trials":2320,"activeCount":96},[],{"trials":2322,"activeCount":96},[],{"trials":2324,"activeCount":96},[],{"trials":2326,"activeCount":96},[],{"intervention":2328,"totalTrials":112,"cells":2329},"Tumor antigen-sensitized DC vaccine and their sensitized T cells subcutaneous administration",{"EARLY_PHASE1":2330,"PHASE1":2332,"PHASE2":2345,"PHASE3":2347,"PHASE4":2349,"NA":2351},{"trials":2331,"activeCount":96},[],{"trials":2333,"activeCount":96},[2334],{"nctId":2335,"briefTitle":2336,"status":222,"phases":2337,"primaryCompletion":2148,"completion":2338,"start":2339,"enrollment":1188,"conditions":2340,"interventions":2344},"NCT05235607","Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors",[85],"2023-12-02","2022-03-01",[2244,2341,2342,2343],"Melanoma","Bladder Cancer","Colorectal Cancer",[2328],{"trials":2346,"activeCount":96},[],{"trials":2348,"activeCount":96},[],{"trials":2350,"activeCount":96},[],{"trials":2352,"activeCount":96},[],{"intervention":195,"totalTrials":112,"cells":2354},{"EARLY_PHASE1":2355,"PHASE1":2357,"PHASE2":2363,"PHASE3":2365,"PHASE4":2367,"NA":2369},{"trials":2356,"activeCount":96},[],{"trials":2358,"activeCount":96},[2359],{"nctId":186,"briefTitle":187,"status":188,"phases":2360,"primaryCompletion":190,"completion":191,"start":192,"enrollment":96,"conditions":2361,"interventions":2362},[85],[28],[195,196,197,178,198],{"trials":2364,"activeCount":96},[],{"trials":2366,"activeCount":96},[],{"trials":2368,"activeCount":96},[],{"trials":2370,"activeCount":96},[],{"intervention":2372,"totalTrials":112,"cells":2373},"Dual-targeting VEGFR1 and PD-L1 CAR-T cells",{"EARLY_PHASE1":2374,"PHASE1":2376,"PHASE2":2388,"PHASE3":2390,"PHASE4":2392,"NA":2394},{"trials":2375,"activeCount":96},[],{"trials":2377,"activeCount":96},[2378],{"nctId":2379,"briefTitle":2380,"status":222,"phases":2381,"primaryCompletion":1925,"completion":1925,"start":2382,"enrollment":468,"conditions":2383,"interventions":2387},"NCT05477927","Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases",[85],"2023-11-28",[2384,2385,2386],"Malignant Peritoneal Effusion","Malignant Ascites","Serous Cavity Metastatises",[2372],{"trials":2389,"activeCount":96},[],{"trials":2391,"activeCount":96},[],{"trials":2393,"activeCount":96},[],{"trials":2395,"activeCount":96},[],{"intervention":2397,"totalTrials":112,"cells":2398},"Anlotinib Hydrochloride",{"EARLY_PHASE1":2399,"PHASE1":2401,"PHASE2":2414,"PHASE3":2416,"PHASE4":2418,"NA":2420},{"trials":2400,"activeCount":96},[],{"trials":2402,"activeCount":96},[2403],{"nctId":2404,"briefTitle":2405,"status":343,"phases":2406,"primaryCompletion":2407,"completion":573,"start":2408,"enrollment":2409,"conditions":2410,"interventions":2413},"NCT04012619","Anlotinib Hydrochloride Combined With AP in Stage IIIB\u002FIIIC\u002FIV Non-squamous Non-small-cell Lung Cancer",[85],"2019-11-05","2019-04-30",8,[2411,2412],"Non-squamous Non-small-cell Lung Cancer","Anlotinib",[2397],{"trials":2415,"activeCount":96},[],{"trials":2417,"activeCount":96},[],{"trials":2419,"activeCount":96},[],{"trials":2421,"activeCount":96},[],{"intervention":2423,"totalTrials":112,"cells":2424},"Dobutamine hydrochloride, Injectable",{"EARLY_PHASE1":2425,"PHASE1":2438,"PHASE2":2440,"PHASE3":2442,"PHASE4":2444,"NA":2446},{"trials":2426,"activeCount":96},[2427],{"nctId":2428,"briefTitle":2429,"status":222,"phases":2430,"primaryCompletion":2431,"completion":2432,"start":2433,"enrollment":8,"conditions":2434,"interventions":2436},"NCT06210217","Effect of TEE-guided Non-fluid Limited Combined With Dobutamine on Hepatic Venous Blood Flow Spectrum",[84],"2024-03-30","2024-04-07","2024-02-01",[2435],"Laparoscopic Hepatectomy",[2423,2437],"0.9% normal saline",{"trials":2439,"activeCount":96},[],{"trials":2441,"activeCount":96},[],{"trials":2443,"activeCount":96},[],{"trials":2445,"activeCount":96},[],{"trials":2447,"activeCount":96},[],{"intervention":2437,"totalTrials":112,"cells":2449},{"EARLY_PHASE1":2450,"PHASE1":2456,"PHASE2":2458,"PHASE3":2460,"PHASE4":2462,"NA":2464},{"trials":2451,"activeCount":96},[2452],{"nctId":2428,"briefTitle":2429,"status":222,"phases":2453,"primaryCompletion":2431,"completion":2432,"start":2433,"enrollment":8,"conditions":2454,"interventions":2455},[84],[2435],[2423,2437],{"trials":2457,"activeCount":96},[],{"trials":2459,"activeCount":96},[],{"trials":2461,"activeCount":96},[],{"trials":2463,"activeCount":96},[],{"trials":2465,"activeCount":96},[],{"intervention":2467,"totalTrials":112,"cells":2468},"ZA-001",{"EARLY_PHASE1":2469,"PHASE1":2480,"PHASE2":2482,"PHASE3":2484,"PHASE4":2486,"NA":2488},{"trials":2470,"activeCount":96},[2471],{"nctId":2472,"briefTitle":2473,"status":343,"phases":2474,"primaryCompletion":2475,"completion":2475,"start":2476,"enrollment":9,"conditions":2477,"interventions":2479},"NCT06359821","Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry in Metastatic Castration Resistant Prostate Cancer",[84],"2024-10-14","2024-05-17",[2478],"Metastatic Prostate Cancer",[2467],{"trials":2481,"activeCount":96},[],{"trials":2483,"activeCount":96},[],{"trials":2485,"activeCount":96},[],{"trials":2487,"activeCount":96},[],{"trials":2489,"activeCount":96},[],{"intervention":2491,"totalTrials":112,"cells":2492},"pembrolizumab",{"EARLY_PHASE1":2493,"PHASE1":2495,"PHASE2":2497,"PHASE3":2499,"PHASE4":2501,"NA":2503},{"trials":2494,"activeCount":96},[],{"trials":2496,"activeCount":96},[],{"trials":2498,"activeCount":96},[],{"trials":2500,"activeCount":96},[],{"trials":2502,"activeCount":96},[],{"trials":2504,"activeCount":96},[2505],{"nctId":2506,"briefTitle":2507,"status":222,"phases":2508,"primaryCompletion":2509,"completion":588,"start":2510,"enrollment":1188,"conditions":2511,"interventions":2512},"NCT03373955","A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients",[],"2021-07-31","2017-11-23",[761],[2491],{"intervention":2514,"totalTrials":112,"cells":2515},"2% lidocaine",{"EARLY_PHASE1":2516,"PHASE1":2518,"PHASE2":2520,"PHASE3":2522,"PHASE4":2524,"NA":2526},{"trials":2517,"activeCount":96},[],{"trials":2519,"activeCount":96},[],{"trials":2521,"activeCount":96},[],{"trials":2523,"activeCount":96},[],{"trials":2525,"activeCount":96},[],{"trials":2527,"activeCount":96},[2528],{"nctId":2529,"briefTitle":2530,"status":343,"phases":2531,"primaryCompletion":2532,"completion":2532,"start":2533,"enrollment":6,"conditions":2534,"interventions":2536},"NCT00798018","Effect of Intra-cuff Lidocaine and Tetracaine on Tracheal Tube-induced Emergence Phenomena",[89],"2009-02","2008-10",[2535],"Pharyngitis",[2514,2537,2538],"1% tetracaine","N.S",{"intervention":2537,"totalTrials":112,"cells":2540},{"EARLY_PHASE1":2541,"PHASE1":2543,"PHASE2":2545,"PHASE3":2547,"PHASE4":2549,"NA":2551},{"trials":2542,"activeCount":96},[],{"trials":2544,"activeCount":96},[],{"trials":2546,"activeCount":96},[],{"trials":2548,"activeCount":96},[],{"trials":2550,"activeCount":96},[],{"trials":2552,"activeCount":96},[2553],{"nctId":2529,"briefTitle":2530,"status":343,"phases":2554,"primaryCompletion":2532,"completion":2532,"start":2533,"enrollment":6,"conditions":2555,"interventions":2556},[89],[2535],[2514,2537,2538],{"intervention":2538,"totalTrials":112,"cells":2558},{"EARLY_PHASE1":2559,"PHASE1":2561,"PHASE2":2563,"PHASE3":2565,"PHASE4":2567,"NA":2569},{"trials":2560,"activeCount":96},[],{"trials":2562,"activeCount":96},[],{"trials":2564,"activeCount":96},[],{"trials":2566,"activeCount":96},[],{"trials":2568,"activeCount":96},[],{"trials":2570,"activeCount":96},[2571],{"nctId":2529,"briefTitle":2530,"status":343,"phases":2572,"primaryCompletion":2532,"completion":2532,"start":2533,"enrollment":6,"conditions":2573,"interventions":2574},[89],[2535],[2514,2537,2538]]